

DAFTAR PUSTAKA

1. Huang Y, Ge H, Wang X, Zhang X. Association between blood lipid levels and lower extremity deep venous thrombosis: a population-based cohort study. *Clinical and Applied Thrombosis/Hemostasis*. 2022;28:1–8.
2. Brill A. Multiple facets of venous thrombosis. *International Journal of Molecular Science*. 2021;22:1–3.
3. Tambunan K, Kurnianda J, Suharti C, Wardhani SO, Sukrisman L, Sutandyo N, et al. IDENTIA registry: incidence of deep vein thrombosis in medically ill subjects at high risk in indonesia: a prospective study. *Acta Medica Indonesiana-The Indonesian Journal of Internal Medicine*. 2020;52:14–24.
4. Behraves S, Hoang P, Nanda A, Wallace A, Sheth RA, Deipolyi AR, et al. Pathogenesis of thromboembolism and endovascular management. *Thrombosis*. 2017;1–13.
5. Stone J, Hangge P, Albadawi H, Wallace A, Shamoun F, Knuttien MG, et al. Deep vein thrombosis: pathogenesis, diagnosis, and medical management. *Cardiovascular Diagnosis and Therapy*. 2017;7:S276–84.
6. Hendi R, Marfen Djajakusumah T, Hapsari P. Hubungan tirah baring lama dengan terjadinya deep vein thrombosis pada pasien rawat bedah. *Medika Kartika*. 2018;2(1):1–4.
7. Kahn SR, Galanaud JP, Vedantham S, Ginsberg JS. Guidance for the prevention and treatment of the post-thrombotic syndrome. 2016;41(1):144–53.
8. Jiang Z, Ma J, Wang Q, Wu F, Ping J, Ming L. Circulating microRNA expression and their target genes in deep vein thrombosis: A systematic review and bioinformatics analysis. *Medicine (United States)*. 2017;96(50):1–7.
9. Califf RM. Biomarker definitions and their applications. *Experimental Biology and Medicine*. 2018;243(3):213–21.
10. Weitz JI, Fredenburgh JC, Eikelboom JW. A test in context: D-dimer. *Journal of the American College of Cardiology*. 2017;70:2411–20.
11. Riondino S, Ferroni P, Zanzotto FM, Roselli M, Guadagni F. Predicting VTE in cancer patients: Candidate biomarkers and risk assessment models. *Cancers (Basel)*. 2019;11:1–23.

12. Kellermair J, Fellner A, Bittinger A, Schneider S, Akbari K, Kammeler J, et al. Soluble platelet endothelial cell adhesion molecule 1 (sPECAM-1) improves diagnostic accuracy of D-Dimer in patients with suspected deep vein thrombosis (DVT). *Journal of Thrombosis and Thrombolysis*. 2020;50:380–5.
13. Legnani C, Libra A, Palareti G, Cosmi B. D-Dimers in diagnosis and prevention of venous thrombosis: recent advances and their practical implications. 2023;133(11):1–10.
14. Bhatt M, Braun C, Patel P, Patel P, Begum H, Wiercioch W, et al. Diagnosis of deep vein thrombosis of the lower extremity: A systematic review and meta-analysis of test accuracy. *Blood Advances*. 2020;4(7):1250–64.
15. Karande GY, Hedgire SS, Sanchez Y, Baliyan V, Mishra V, Ganguli S, et al. Advanced imaging in acute and chronic deep vein thrombosis. Vol. 6, *Cardiovascular Diagnosis and Therapy*. AME Publishing Company; 2016. p. 493–507.
16. Wang S, Wang F, Ren J, Yang H. LncRNA NEAT1 promotes vascular endothelial cell Dysfunction via miR-218-5p/GAB2 and serves as a diagnostic biomarker for deep vein thrombosis. *Clinical and Applied Thrombosis/Hemostasis*. 2023;29:1–11.
17. Jacobs B, Obi A, Wakefield T. Diagnostic biomarkers in venous thromboembolic disease. *Journal of Vascular Surgery Venous and Lymphatic Disorders*. 2016;4:508–17.
18. Anghel L, Sascău R, Radu R, Stătescu C. From classical laboratory parameters to novel biomarkers for the diagnosis of venous thrombosis. *International Journal of Molecular Sciences*. 2020;21:1–18.
19. He X, Liu Y, Li Y, Wu K. Long non-coding RNA crndc promotes deep vein thrombosis by sequestering miR-181a-5p away from thrombogenic Pcyox11. *Thrombosis Journal*. 2023 Dec;21(1).
20. Zhou K, Li N, Qi J, Tu P, Yang Y, Duan H. Diagnostic and prognostic potential of long non-coding RNA NORAD in patients with acute deep vein thrombosis and its role in endothelial cell function. *Thrombosis Journal*. 2024;22.
21. Zeng W, Wang Q, Li X, Wang Z, Chi J, Yang Z, et al. Diagnosis of deep vein thrombosis from γ -butylbetaine and l-carnitine in plasma and urine based on untargeted and targeted metabolomics. *Scientific Reports*. 2025;15:1–18.
22. Hu C, Zhao B, Ye Q, Zou J, Li X, Wu H. The diagnostic value of the neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio for deep venous

- thrombosis: A systematic review and meta-analysis. *Clinical and Applied Thrombosis/Hemostasis*. 2023;29:1–12.
23. Meutia S, Roqyal A. Article overview : Deep vein thrombosis. *DIAGNOSA: Jurnal Ilmu Kesehatan dan Keperawatan*. 2024;2(1):97–106.
 24. Setiati S, Alwi I, Sudoyo AW, K. Simadibrata M, Setiyohadi B, Syam AF. Trombosis vena dalam dan emboli paru. In: Sukrisman L, editor. *Buku Ajar Ilmu Penyakit Dalam*. 6th ed. Jakarta: InternaPublishing; 2014. p. 2818–22.
 25. Mukhopadhyay S, Johnson TA, Duru N, Buzza MS, Pawar NR, Sarkar R, et al. Fibrinolysis and inflammation in venous thrombus resolution. *Frontiers in Immunology*. 2019;10:1–14.
 26. Lee LH, Gallus A, Jindal R, Wang C, Wu CC. Incidence of venous thromboembolism in asian populations: a systematic review. *Thrombosis and Haemostasis*. 2017;117:2243–60.
 27. Etikasari E, Chayati N. Screening risiko terjadinya deep vein thrombosis. *Journal of Telenursing (JOTING)*. 2021;3(2):735–43.
 28. Verian E, Arnold Sihite T, Prasetya D. Karakteristik pasien trombosis vena dalam: tinjauan sistematik. 2021;71(4):161–9.
 29. Wendelboe AM, Raskob GE. Global burden of thrombosis: epidemiologic aspects. *Circulation Research*. 2016;118(9):1340–7.
 30. Lutsey PL, Zakai NA. Epidemiology and prevention of venous thromboembolism. *Nature Review Cardiology*. 2023;20:248–62.
 31. Branchford BR, Carpenter SL. The role of inflammation in venous thromboembolism. *Frontiers in Pediatrics*. 2018;6:1–7.
 32. Cao J, Li S, Ma Y, Li Z, Liu G, Liu Y, et al. Risk factors associated with deep venous thrombosis in patients with different bed-rest durations: A multi-institutional case-control study. *International Journal of Nursing Studies*. 2021;114:1–18.
 33. Schulman S, Makatsariya A, Khizroeva J, Bitsadze V, Kapanadze D. The basic principles of pathophysiology of venous thrombosis. *International Journal of Molecular Sciences*. 2024;25:1–17.
 34. Reddel CJ, Tan CW, Chen VM. Thrombin generation and cancer: Contributors and consequences. *Cancers (Basel)*. 2019;11:1–20.

35. Pastori D, Cormaci VM, Marucci S, Franchino G, Del Sole F, Capozza A, et al. A comprehensive review of risk factors for venous thromboembolism: from epidemiology to pathophysiology. *International Journal of Molecular Sciences*. 2023;24:1–24.
36. Pintaningrum Y, Basuki R, Ermawan R. Trombosis vena dalam dan iskemia tungkai akut. In: Wulandari H, editor. *Buku Ajar Ilmu Penyakit Jantung dan Pembuluh Darah*. Bali: PT. Percetakan Bali; 2019. p. 165–96.
37. Sherwood L. The blood vessels and blood pressure. In: *Human physiology : from cells to systems*. 9th edition. Boston: Cengage Learning; 2016. p. 335–79.
38. Kushner A, P. West W, Suheb MZK, Pillarisetty. LS. Virchow triad [Internet]. 2024 [cited 2025 Apr 8]. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK539697/>
39. Hosseinzadegan H, Tafti DK. Prediction of thrombus growth: effect of stenosis and reynolds number. *Cardiovascular Engineering and Technology*. 2017;8(2):164–81.
40. Khan F, Tritschler T, Kahn SR, Rodger MA. Venous thromboembolism. *The Lancet*. 2021;398:64–77.
41. Kamila AS, Ginuluh GD, Syakir SA, Abida AN, Balqis AA, Karlina F, et al. Deep vein thrombosis (DVT): a literature review. *Jurnal Biologi Tropis*. 2024;24(1b):498–505.
42. Wang KL, Yap ES, Goto S, Zhang S, Siu CW, Chiang CE. The diagnosis and treatment of venous thromboembolism in asian patients. *Thrombosis Journal*. 2018;16:1–12.
43. Wenger N, Sebastian T, Engelberger RP, Kucher N, Spirk D. Pulmonary embolism and deep vein thrombosis: Similar but different. *Thrombosis Research*. 2021;206:88–98.
44. Winter MP, Schernthaner GH, Lang IM. Chronic complications of venous thromboembolism. *Journal of Thrombosis and Haemostasis*. 2017;15:1531–40.
45. Adeniyi O, Aguel F, Agyeman A, Amur S, Brady LS, Grabb MC, et al. Diagnostic biomarker. In: FDA-NIH Biomarker Working Group, editor. *BEST (Biomarkers, EndpointS, and other Tools) Resource*. Amerika: Food and Drug Administration; 2016. p. 5–7.
46. Parpia S, Takach Lapner S, Schutgens R, Elf J, Geersing GJ, Kearon C. Clinical pre-test probability adjusted versus age-adjusted D-dimer interpretation strategy

for DVT diagnosis: A diagnostic individual patient data meta-analysis. *Journal of Thrombosis and Haemostasis*. 2020;18:669–75.

47. Sujana KY, Semadi IN, Mahadewa TGB. The correlation of neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio compared to d-dimer as a diagnostic test in deep vein thrombosis (DVT). *Bali Medical Journal*. 2020;9(2):546–52.
48. Fraser K, Roy NC, Goumidi L, Verdu A, Suchon P, Leal-Valentim F, et al. Plasma biomarkers and Identification of resilient metabolic disruptions in patients with venous thromboembolism using a metabolic systems approach. *Arteriosclerosis, Thrombosis, and Vascular Biology*. 2020;40:2527–38.
49. Dou X, Ma Y, Qin Y, Dong Q, Zhang S, Tian R, et al. NEAT1 silencing alleviates pulmonary arterial smooth muscle cell migration and proliferation under hypoxia through regulation of miR-34a-5p/KLF4 in vitro. *Molecular Medicine Reports*. 2021;24:1–10.
50. V S, Mohanty S, Das D, Ghosh A, Maiti R, Nanda P. Hematological parameters as an early marker of deep vein thrombosis in diabetes mellitus: An observational study. *Cureus*. 2023;15(3):1–9.
51. Rinaldi I, Hamonangan R, Azizi MS, Cahyanur R, Wirawan F, Fatya AI, et al. Diagnostic value of neutrophil lymphocyte ratio and D-Dimer as biological markers of deep vein thrombosis in patients presenting with unilateral limb edema. *Journal Blood Medicine*. 2021;12:313–25.
52. Velioğlu Y, Yüksel A. Utility of platelet-to-lymphocyte ratio to support the diagnosis of acute deep vein thrombosis. *Turkish Journal of Thoracic and Cardiovascular Surgery*. 2019;27(4):493–8.
53. Febra C, Saraiva J, Vaz F, Macedo J, Al-Hroub HM, Semreen MH, et al. Acute venous thromboembolism plasma and red blood cell metabolomic profiling reveals potential new early diagnostic biomarkers: observational clinical study. *Journal of Translational Medicine*. 2024;22:1–17.
54. Alhabibi AM, Eldewi DM, Wahab MAA, Farouk N, El-Hagrasy HA, Saleh OI. Platelet-derived growth factor-beta as a new marker of deep venous thrombosis. *Journal of Research in Medical Sciences*. 2019;24(48):1–6.
55. Memon AA, Sundquist K, PirouziFard M, Elf JL, Strandberg K, Svensson PJ, et al. Identification of novel diagnostic biomarkers for deep venous thrombosis. *British Journal of Haematology*. 2018 May 1;181(3):378–85.

56. Zang X, Su Y, Zhang W, Cao X, Li C, Lu S, et al. Hepatocyte-derived microparticles as novel biomarkers for the diagnosis of deep venous thrombosis in trauma patients. *Clinical and Applied Thrombosis/Hemostasis*. 2023;29:1–12.
57. Wang Q, Chi J, Zeng W, Xu F, Li X, Wang Z, et al. Discovery of crucial cytokines associated with deep vein thrombus formation by protein array analysis. *BMC Cardiovascular Disorders*. 2024;24:1–10.
58. Riva N, Vella K, Hickey K, Bertù L, Zammit D, Spiteri S, et al. Biomarkers for the diagnosis of venous thromboembolism: D-dimer, thrombin generation, procoagulant phospholipid and soluble P-selectin. *Journal of Clinical Pathology*. 2018;0:1–8.
59. Saadeldin AA, El-Sakhawy YN, Hussien HA. Soluble P-selectin level in patients with deep venous thrombosis. *Egyptian Journal of Hospital Medicine*. 2018 Jan;70(9):1529–38.
60. Schaefer JK, Angelini DE, Hawley A, Blackburn SA, Lusk E, Braun TM, et al. Biomarkers and clinical prediction rules in the diagnosis of suspected deep vein thrombosis: A comparison of cancer and non-cancer patients. *Blood*. 2016;128(22).
61. Purdy M, Obi A, Myers D, Wakefield T. P- and E- selectin in venous thrombosis and non-venous pathologies. Vol. 20, *Journal of Thrombosis and Haemostasis*. John Wiley and Sons Inc; 2022. p. 1056–66.
62. von zur Mühlen C, Koeck T, Schiffer E, Sackmann C, Zürlig P, Hilgendorf I, et al. Urine proteome analysis as a discovery tool in patients with deep vein thrombosis and pulmonary embolism. *Proteomics Clinical Applications*. 2016;10:574–84.
63. Pan Z, Zhang Y, Li C, Yin Y, Liu R, Zheng G, et al. MiR-296-5p ameliorates deep venous thrombosis by inactivating S100A4. *Experimental Biology and Medicine*. 2021;0:1–10.
64. Zhang D, Cheng C, Yang M, Zhang X, Yu X, Wang M. MicroRNA-181b-5p/HEY2 axis is involved in the progress of deep venous thrombosis via mediating vascular endothelial injury. *Hematology (United Kingdom)*. 2024;29:1–8.
65. Chang Y, Wang C, Zheng Y, Wang Q. Circulating microRNA-423-5p serves as a potential diagnostic biomarker in elderly patients with deep-vein thrombosis. *International Journal of Clinical and Experimental Medicine*. 2019;12(6):7065–73.

66. Shiotsu hiromichi, Sueta D, Shinriki S, Ryu M, Usuku H, Nakata M, et al. miR-4485-5p in large extracellular vesicles as a new potent biomarker for diagnosis of deep vein thrombosis. *Laboratory Medicine International*. 2024;3(3):2024–95.
67. Jiang Z, Ma J, Wang Q, Wu F, Ping J, Ming L. Combination of circulating miRNA-320a/b and D-dimer improves diagnostic accuracy in deep vein thrombosis patients. *Medical Science Monitor*. 2018;24:2031–7.
68. Xu L, Ji C, Miao X, Ge J, Li F, Xu C. Combination of circulating miR-125a-5p, miR-223-3p and D-dimer as a novel biomarker for deep vein thrombosis. *American Journal of the Medical Sciences*. 2022;364(5):601–11.
69. Wang X, Sundquist K, Elf JL, Strandberg K, Svensson PJ, Hedelius A, et al. Diagnostic potential of plasma microRNA signatures in patients with deep-vein thrombosis. *Journal of Thrombosis and Haemostasis*. 2016;116(2):328–36.
70. Antoun C, Wikan VE, Øverli Ø, Ueland T, Yeganeh GJ, Brækkan SK, et al. Plasma microRNA-145-5p as a diagnostic biomarker for acute deep vein thrombosis. *Research and Practice in Thrombosis and Haemostasis*. 2025;9:1–8.
71. Li M, Li Y, Zhang D, Cheng C, Yang M, Zhang X, et al. Assisting significance of lncRNA ASB16-AS1 in the early detection and prognosis prediction of patients with deep venous thrombosis. *BMC Cardiovascular Disorders*. 2025;25:1–9.

